Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Cohort Study.

Autor: Hernández-Preciado MR; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico.; Neurosciences Division, Western Biomedical Research Center (IMSS), Guadalajara 44340, Mexico., Marquez-Pedroza J; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico., Sánchez-Rosales NA; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico., García-Rivera JJ; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico., Kobayashi-Gutiérrez A; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico., Torres-Mendoza BM; Neurosciences Division, Western Biomedical Research Center (IMSS), Guadalajara 44340, Mexico.; Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Mexico., Chavarría-Avila E; Department of Philosophical and Methodological Disciplines, University Health Sciences Center, University of Guadalajara, Guadalajara 44340, Mexico., Montaño-Serrano RA; Department of Physiology, University of Guadalajara, Guadalajara 44340, Mexico., Cortes-Enriquez F; Department of Neurology, Hospital General Regional No 45 of the Mexican Institute of Social Security, Guadalajara 44910, Mexico., Mireles-Ramírez MA; High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2022 Jun 22; Vol. 11 (13). Date of Electronic Publication: 2022 Jun 22.
DOI: 10.3390/jcm11133584
Abstrakt: The objective of this study was to evaluate the clinical files of patients with RRMS who started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or fingolimod (FTY)). This was a historical cohort study. We compared the effect according to the Expanded Disability Status Scale (EDSS) and the number of relapses in RRMS patients receiving these treatments after a mean period of 12 months. We found a statistically significant difference (p < 0.001) when comparing the EDSS scores and the annual relapse rates of patients receiving RTX with those receiving NTZ or FTY. This study is essential for our clinical practice, since patients with limited treatment options represent a challenge with regard to the management of their medical care. However, clinical trials and prospective studies with long follow-up periods are necessary to provide sufficient evidence on the efficacy of RTX and thus include this treatment in the therapeutic profile of patients with MS.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje